Jeffrey del Carmen - 26 Nov 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Commercial Officer
Signature
/s/ Jeffrey Del Carmen
Issuer symbol
CPRX
Transactions as of
26 Nov 2025
Net transactions value
-$210,006
Form type
4
Filing time
28 Nov 2025, 17:00:06 UTC
Previous filing
24 Nov 2025
Next filing
10 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Del Carmen Jeffrey Chief Commercial Officer 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES /s/ Jeffrey Del Carmen 28 Nov 2025 0001816477

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $46,238 +10,983 +277% $4.21 14,945 26 Nov 2025 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale $256,244 -10,983 -73% $23.33 3,962 26 Nov 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 +10,983 +1.1% $0.000000 1,053,552 26 Nov 2025 Common Stock 10,983 $4.21 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.
F2 Shares were sold in various lots from $23.331 to $23.345 per share. The price listed represents a weighted average price for the shares sold.
F3 Options previously vested in three annual tranches beginning on January 6, 2021.